Back to News
Market Impact: 0.35
Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study
Source: Nasdaq
Healthcare & Biotech
Abbisko Therapeutics reported preliminary Phase II results showing lavengratinib (ABSK061) improved growth rates in children with achondroplasia. The investigational therapy also maintained a favorable safety profile, supporting its clinical development outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Globus Medical stock holds at Neutral as BTIG cites revenue miss
- Canaccord reiterates Natera stock rating on strong Q3 results
- BMO Capital downgrades Strategic Education stock rating on enrollment declines
- Mizuho raises Tandem Diabetes Care stock price target on Q3 beat
- Canaccord raises iRhythm stock price target on strong margins